Skip to main
AMGN

Amgen (AMGN) Stock Forecast & Price Target

Amgen (AMGN) Analyst Ratings

Based on 18 analyst ratings
Hold
Strong Buy 11%
Buy 22%
Hold 61%
Sell 6%
Strong Sell 0%

Bulls say

Amgen's stock outlook is bolstered by a significant 40% increase in sales during the third quarter of 2025 compared to the same period in 2024, reflecting strong performance across various product lines. The company has successfully launched multiple drugs, with notable growth for Repatha and Tezspire, which saw new prescriptions increase by approximately 44% and 60%, respectively, through October 2025 compared to the previous year. Additionally, Amgen raised its fiscal year 2025 revenue guidance to between $35.8 billion and $36.6 billion, indicating robust performance across its established franchises and a positive trajectory for products like Uplizna, which is projected to reach $1.4 billion in sales by 2027.

Bears say

Amgen's financial outlook appears negative due to projected total revenue growth of only approximately 1% in 2026, significantly impacted by anticipated annual sales declines of about 28% for Prolia and 39% for Xgeva. Additionally, the company's R&D spending growth is expected to be more subdued, further constraining the potential for innovative product development amidst a competitive landscape. Finally, the lack of long-term growth drivers and uncertainty surrounding emerging products like MariTide and olpasiran to offset declining revenues from maturing products contribute to concerns about Amgen's sustainability in the face of imminent loss of exclusivity for key franchises.

Amgen (AMGN) has been analyzed by 18 analysts, with a consensus rating of Hold. 11% of analysts recommend a Strong Buy, 22% recommend Buy, 61% suggest Holding, 6% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Amgen and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Amgen (AMGN) Forecast

Analysts have given Amgen (AMGN) a Hold based on their latest research and market trends.

According to 18 analysts, Amgen (AMGN) has a Hold consensus rating as of Apr 6, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $348.67, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $348.67, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Amgen (AMGN)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.